Cargando…

Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines

BACKGROUND: Platinum derivatives are used widely for the treatment of many cancers. However, the toxicity that is observed makes imperative the need for new drugs, or new combinations. Anvirzel™ is an extract which has been demonstrated with experimental data that displays anticancer activity. The a...

Descripción completa

Detalles Bibliográficos
Autores principales: Apostolou, Panagiotis, Toloudi, Maria, Chatziioannou, Marina, Ioannou, Eleni, Knocke, Dennis R, Nester, Joe, Komiotis, Dimitrios, Papasotiriou, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637172/
https://www.ncbi.nlm.nih.gov/pubmed/23521834
http://dx.doi.org/10.1186/2050-6511-14-18
_version_ 1782267422573592576
author Apostolou, Panagiotis
Toloudi, Maria
Chatziioannou, Marina
Ioannou, Eleni
Knocke, Dennis R
Nester, Joe
Komiotis, Dimitrios
Papasotiriou, Ioannis
author_facet Apostolou, Panagiotis
Toloudi, Maria
Chatziioannou, Marina
Ioannou, Eleni
Knocke, Dennis R
Nester, Joe
Komiotis, Dimitrios
Papasotiriou, Ioannis
author_sort Apostolou, Panagiotis
collection PubMed
description BACKGROUND: Platinum derivatives are used widely for the treatment of many cancers. However, the toxicity that is observed makes imperative the need for new drugs, or new combinations. Anvirzel™ is an extract which has been demonstrated with experimental data that displays anticancer activity. The aim of the present study is to determine whether the combination of Cisplatin and Anvirzel™ has a synergistic effect against different types of cancer. MATERIALS AND METHODS: To measure the efficacy of treatment with Cisplatin and Anvirzel™, methyl-tetrazolium dye (MTT) chemosensitivity assays were used incorporating established human cancer cell lines. Measurements were performed in triplicates, three times, using different incubation times and different concentrations of the two formulations in combination or on their own. t-test was used for statistical analysis. RESULTS: In the majority of the cell lines tested, lower concentrations of Anvirzel™ induced a synergistic effect when combined with low concentrations of Cisplatin after an incubation period of 48 to 72 h. The combination of Anvirzel™/Cisplatin showed anti-proliferative effects against a wide range of tumours. CONCLUSION: The results showed that the combination of Anvirzel™ and Cisplatin is more effective than monotherapy, even when administered at low concentrations; thus, undesirable toxic effects can be avoided.
format Online
Article
Text
id pubmed-3637172
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36371722013-04-27 Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines Apostolou, Panagiotis Toloudi, Maria Chatziioannou, Marina Ioannou, Eleni Knocke, Dennis R Nester, Joe Komiotis, Dimitrios Papasotiriou, Ioannis BMC Pharmacol Toxicol Research Article BACKGROUND: Platinum derivatives are used widely for the treatment of many cancers. However, the toxicity that is observed makes imperative the need for new drugs, or new combinations. Anvirzel™ is an extract which has been demonstrated with experimental data that displays anticancer activity. The aim of the present study is to determine whether the combination of Cisplatin and Anvirzel™ has a synergistic effect against different types of cancer. MATERIALS AND METHODS: To measure the efficacy of treatment with Cisplatin and Anvirzel™, methyl-tetrazolium dye (MTT) chemosensitivity assays were used incorporating established human cancer cell lines. Measurements were performed in triplicates, three times, using different incubation times and different concentrations of the two formulations in combination or on their own. t-test was used for statistical analysis. RESULTS: In the majority of the cell lines tested, lower concentrations of Anvirzel™ induced a synergistic effect when combined with low concentrations of Cisplatin after an incubation period of 48 to 72 h. The combination of Anvirzel™/Cisplatin showed anti-proliferative effects against a wide range of tumours. CONCLUSION: The results showed that the combination of Anvirzel™ and Cisplatin is more effective than monotherapy, even when administered at low concentrations; thus, undesirable toxic effects can be avoided. BioMed Central 2013-03-25 /pmc/articles/PMC3637172/ /pubmed/23521834 http://dx.doi.org/10.1186/2050-6511-14-18 Text en Copyright © 2013 Apostolou et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Apostolou, Panagiotis
Toloudi, Maria
Chatziioannou, Marina
Ioannou, Eleni
Knocke, Dennis R
Nester, Joe
Komiotis, Dimitrios
Papasotiriou, Ioannis
Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
title Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
title_full Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
title_fullStr Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
title_full_unstemmed Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
title_short Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
title_sort anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637172/
https://www.ncbi.nlm.nih.gov/pubmed/23521834
http://dx.doi.org/10.1186/2050-6511-14-18
work_keys_str_mv AT apostoloupanagiotis anvirzelincombinationwithcisplatininbreastcolonlungprostatemelanomaandpancreaticcancercelllines
AT toloudimaria anvirzelincombinationwithcisplatininbreastcolonlungprostatemelanomaandpancreaticcancercelllines
AT chatziioannoumarina anvirzelincombinationwithcisplatininbreastcolonlungprostatemelanomaandpancreaticcancercelllines
AT ioannoueleni anvirzelincombinationwithcisplatininbreastcolonlungprostatemelanomaandpancreaticcancercelllines
AT knockedennisr anvirzelincombinationwithcisplatininbreastcolonlungprostatemelanomaandpancreaticcancercelllines
AT nesterjoe anvirzelincombinationwithcisplatininbreastcolonlungprostatemelanomaandpancreaticcancercelllines
AT komiotisdimitrios anvirzelincombinationwithcisplatininbreastcolonlungprostatemelanomaandpancreaticcancercelllines
AT papasotiriouioannis anvirzelincombinationwithcisplatininbreastcolonlungprostatemelanomaandpancreaticcancercelllines